Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

SGLT2 inhibitors breathe life into kidney-disease care

Researchers want to expand the use of drugs that protect the hearts and kidneys of people with chronic kidney disease.
  1. Amanda B. Keener

    1. Amanda B. Keener is a science writer in Littleton, Colorado.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Illustration of a kidney-shaped garden partially on fire. A blue fire truck is spraying it with white drug powder to put it off.

Credit: Eva Vazquez

During his 25 years as a nephrologist, Hans-Joachim Anders has travelled to many conferences on kidney disease. On his return, his patients often ask him if he has learnt anything relevant to them. For more than two decades, “I had to tell them no”, says Anders, who is at the Ludwig Maximilian University of Munich in Germany.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 615, S2-S4 (2023)

doi: https://doi.org/10.1038/d41586-023-00648-3

This article is part of Nature Outlook: Chronic kidney disease, an editorially independent supplement produced with the financial support of third parties. About this content.

Updates & Corrections

  • Clarification 27 April 2023: This Outlook article originally stated that SGLT2 inhibitors were first approved in 2013. That date is when they were approved in the United States; they were approved in the European Union in 2012.

References

  1. Meraz-Muñoz, A. Y., Weinstein, J. & Wald, R. Kidney360 2, 1042–1047 (2021).

    Article  PubMed  Google Scholar 

  2. The EMPA-KIDNEY Collaborative Group. N. Engl. J. Med. 388, 117–127 (2023).

    Article  PubMed  Google Scholar 

  3. McGuire, D. K. et al. JAMA Cardiol. 6, 148–158 (2021).

    Article  PubMed  Google Scholar 

  4. Perkovic, V. et al. N. Engl. J. Med. 380, 2295–2306 (2019).

    Article  PubMed  Google Scholar 

  5. Heerspink, J. L. et al. N. Engl. J. Med. 383, 1436–1446 (2020).

    Article  PubMed  Google Scholar 

  6. Yau, K. et al. Kidney Int. Rep. 7, 1463–1476 (2022).

    Article  PubMed  Google Scholar 

  7. Song, C. et al. Am. J. Transplant. 22 (suppl. 3), abstr. 30 (2022).

  8. Menzies, R. I. et al. Am. Soc. Nephrol. abstr. PUB361 (2022).

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links